Sleep Disorders Trial, Recruiting NCT07355842 Sponsor: University of Zurich Condition: Sleep Disorders
Back to Sleep Disorders

Sleep Disorders Trial, Recruiting

NCT07355842
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have signed a consent form agreeing to take part
  • People who have been diagnosed with isolated REM Sleep Behavior Disorder (a sleep condition where a person acts out dreams), confirmed by an overnight sleep study, AND who also either: have early signs of movement difficulties plus an abnormal sense of smell, OR have been diagnosed with Parkinson's disease for less than 2 years
  • People who are not currently taking, and are not expected to start taking, medications that affect dopamine levels during the study
  • People who are able to use the study device on their own or with the help of someone they live with, and who have a stable living situation
  • People with sufficient skills in German, French, or Italian
  • Women who could become pregnant must have a negative pregnancy test at the time of joining

Who may not be able to join:

  • People who have a history of not following other prescribed treatments
  • People who are currently or have recently been part of another clinical trial
  • People who expect to be away for extended periods during the study
  • People with hearing difficulties that would prevent them from hearing the tones used in the study
  • People whose sleep study during the screening phase shows they do not respond to the sound-based stimulation used in this trial
  • People with a significant or unstable medical condition
  • People with a sleep-breathing disorder score above a certain level, or who use a CPAP breathing machine at night
  • People who have Restless Legs Syndrome
  • People who meet the criteria for an atypical form of Parkinson's disease
  • People who have been diagnosed with dementia, or who score below a certain level on a standard memory and thinking test
  • People with severe depression or another significant psychiatric condition
  • People who regularly use sleeping tablets (benzodiazepines) or other substances that slow down the central nervous system
  • People with a current or recent history (within the past year) of substance misuse or heavy alcohol use
  • People who have recently had, or are planning to have, major surgery
  • People with known allergies or sensitivities relevant to skin electrodes or medications used in the study
  • People who do not meet the additional requirements related to the PET brain imaging part of the study (confirm with trial site)
  • People for whom participation would pose any other kind of personal risk
  • Women who are breastfeeding, planning to become pregnant, or who are unwilling to use a reliable form of contraception during the study

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Andreas Luft, Prof. Dr. med., University of Zurich

Phone: +41 44 255 10 43

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
15 January 2026
Est. completion
30 June 2029

Where this trial is recruiting

🇨🇭 Switzerland

Primary endpoints

Presynaptic Dopaminergic Integrity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov